Zook In As Vivus CEO, But Turnaround Depends On Partnering
This article was originally published in The Pink Sheet Daily
Executive Summary
Vivus has a new chairman and CEO after a proxy battle with a dissident shareholder ended in a settlement, but will the new management be able to find a marketing partner for Qsymia or broker an outright sale?
You may also be interested in...
Orexigen Defines A Way To Get The Contrave PDUFA Clock Ticking
The summary report of an interim analysis of the ongoing LIGHT clinical trial evaluating the cardiovascular safety of the obesity medicine can form the basis of a resubmission of the Contrave NDA, the company announced, shaving some time off the PDUFA clock.
First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands
The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.
Wegovy CVOT Data Could Pave The Way For Broad Reimbursement, CEO Says
Novo Nordisk CEO Lars Jørgensen discussed the supply and market access position of its rising obesity drug, Wegovy, during the CNBC Health Returns conference.